SubHero Banner

Nexletol (bempedoic acid) – New drug approval

February 21, 2020 - Esperion announced the FDA approval of Nexletol (bempedoic acid), as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Download PDF